To evaluate the impact of MAP2K1/2 mutations on the transcription of immunity-related genes in melanoma, we integrated and analysed the gene expression data for patients from four clinical cohorts and the TCGA-SKCM cohort. This evidence concerns the gene MAP2K1 and melanoma.